Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 5/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14783859 | 0.87 | CFTR (0.44) | CFTRRXFP1LMNAPOLBCACNA1H | |
| SCHEMBL14783863 | 0.86 | CFTR (0.50) | CFTRMAPK3 | |
| SCHEMBL14783402 | 0.78 | CFTR (0.39) | CFTRRXFP1LMNAPOLBMETAP1 | |
| SCHEMBL30512420 | 0.77 | CFTR (0.34) | CFTRAAK1 | |
| SCHEMBL25378522 | 0.77 | CFTR (0.34) | CFTRAAK1 | |
| SCHEMBL25378538 | 0.77 | CFTR (0.34) | CFTRAAK1 | |
| SCHEMBL25378528 | 0.77 | CFTR (0.34) | CFTRAAK1 | |
| SCHEMBL26195509 | 0.75 | CFTR (0.33) | CFTRAAK1 | |
| SCHEMBL25378893 | 0.74 | CDK1 (0.38) | CFTRRXFP1LMNAPOLBCACNA1H | |
| SCHEMBL31208048 | 0.74 | CDK1 (0.38) | CFTRRXFP1LMNAPOLBCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2755967-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038386-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013038386-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | CFTR, OPRD1, OPRK1 | CFTR 1/4885RXFP1 340/4885LMNA 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.